Meet The Authors
This monumental reference deals with both the high-profile cases and the “uncelebrated decisions” that tend to slip under the radar and fits them into an analytical framework that reveals their true significance. Patents and the Federal Circuit addresses ever-changing issues and developments in substantive patent law, infringement litigation, and procedure. The authors distill the opinions issued by the primary source of governing law on patents, providing convenient, one-source access to controlling case law.
The new Thirteenth Edition adds discussion of the following topics:
The Supreme Court’s decision in SCA Hygiene Products Aktiebolag v. First Quality Baby Products, LLC that laches does not bar damages for patent infringement where the infringement occurred within the 6-year limitations period.
The Federal Circuit’s en banc decision in Medicines Co. v. Hospira, Inc. regarding the scope of a commercial sale for purposes of the on sale bar.
The Supreme Court’s holdings in Impression Products v. Lexmark that single-use/no-sale provisions are unenforceable against third parties and that an authorized sale outside the United States exhausts U.S. patent rights.
Venue following the Supreme Court’s decision in TC Heartland v. Kraft that a corporation resides for purposes of venue only in the state of incorporation.
Liability for infringement of multi-component devices following the Supreme Court’s decision in Promega Corp. v. Life Technologies Corp.
Operation of the so-called “patent dance” under the Biologics Price Competition and Innovation Act (BPCIA), including discussion of the Supreme Court’s decision in Sandoz Inc. v. Amgen Inc. and the Federal Circuit’s decision in Amgen Inc. v. Apotex Inc.
The Federal Circuit’s recognition of an independent patent agent privilege that attaches to some communications between a client and a non-attorney patent agent in In re Queen’s University at Kingston.
The Thirteenth Edition also incorporates the following post-Alice decisions on patentability under 35 U.S.C. § 101:
Rapid Litig. Mgmt. Ltd. v. CellzDirect, Inc.
Intellectual Ventures I LLC v. Symantec Corp.
AMDOCS (Israel) Ltd. V. Openet Telecom, Inc.
Bascom Glob. Internet v. AT&T Mobility, LLC
The new edition adds a number of cases examining claim construction post-Teva v. Sandoz and enhanced damages post-Halo and Stryker, and incorporates many other important Federal Circuit patent law decisions.
The2018 Supplement adds Federal Circuit decisions through the end of 2017, plus selected important 2018 Supreme Court decisions, including Oil States Energy Services v. Greene’s Energy Group, upholding the Federal Circuit’s ruling on the constitutionality of inter partes review (IPR) proceedings and ruling that IPR does not violate either Article III’s grant of judicial power or the Seventh Amendment’s right to a jury trial; SAS Institute, Inc. v. Iancu, in which the Court reversed the Federal Circuit and ruled that the AIA requires the USPTO Director to consider every challenged claim once it decides to institute an IPR proceeding; and WesternGeco LLC v. ION Geophysical Corp., in which the Court held that a patentee may recover damages for lost profits attributable to foreign sales under 35 U.S.C. §271(f).
Key new Federal Circuit decisions include:
Clarification in In re Cray Inc. on analysis for venue after TC Heartland
In re Aqua Products, the Federal Circuit’s 148-page sharply-divided series of five plurality opinions on the standard for motions to amend in post-AIA proceedings before the PTAB
The decision on inequitable conduct in Regeneron Pharmaceuticals, Inc. v. Merus N.V., holding that litigation misconduct can support an inference of specific intent to deceive
The on sale bar decision in Helsinn Healthcare v. Teva Pharmaceuticals, on which the Supreme Court granted certiorari
The en banc decision in Nantkwest, Inc. v. Iancu, holding that the USPTO may not recover its attorney fees as “expenses” when a patent applicant appeals to the district court under 35 U.S.C. §145
The latest additions to the court’s evolving jurisprudence on patent eligibility under 35 U.S.C. §101, including
Cleveland Clinic Found. v. True Health Diagnostics, LLC
Credit Acceptance Corp. v. Westlake Services
Mentor Graphics Corp. v. EVE-USA, Inc.
RecogniCorp, LLC v. Nintendo Co., Ltd.
Return Mail, Inc. v. United States Postal Service
Two-Way Media, Ltd. v. Comcast Cable Communications, LLC
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)